Levels of plasma creatinine — a metabolic product of healthy muscle — are significantly associated with the functional status of amyotrophic lateral sclerosis (ALS) patients, and can help predict their survival, results from a new study show. The findings suggest that plasma creatinine may be an important biomarker…
A shift in the make-up of immune cells found in the blood of patients with amyotrophic lateral sclerosis (ALS) favors specific types of pro-inflammatory T-helper cells in detriment to anti-inflammatory regulatory T-cells, a study has found. This change in immune cells’ balance is associated with disease severity…
A $25,000 Ionis Pharmaceuticals scholarship will help amyotrophic lateral sclerosis (ALS) patients in the San Diego, California, area participate in a host of integrative physical and mental wellness programs through Adapt Functional Movement Center. The full range of personalized sessions will be provided online during the COVID-19 pandemic. Designed…
Seneca Biopharma announced that work is underway to advance NSI-566, its leading stem cell treatment candidate, into a Phase 3 study in people with amyotrophic lateral sclerosis (ALS). The decision followed a meeting with the US Food and Drug Administration (FDA), and is supported by data collected from…
People with amyotrophic lateral sclerosis (ALS) have significantly lower levels of a small molecule called microRNA-335-5p (miR-335-5p), which promotes the degradation of mitochondria and nerve cell death, a study shows. These findings suggest that dysregulation of miR-335-5p may contribute to neurodegeneration in ALS patients, which may be useful…
Fasudil, approved in Japan for treating stroke patients, also is well-tolerated and prevents disease worsening in people with amyotrophic lateral sclerosis (ALS), according to a report of three patients who received the medicine under compassionate use. However, the effects were transient, and all three patients experienced either a decline…
Mutations in the TBK1 gene — often associated with amyotrophic lateral sclerosis (ALS) — seem to have a dual role in progression of the disease, causing it to emerge earlier in animals models of ALS, but then slowing in later stages. This paradoxical role, according to a results…
By blocking the activity of the proteasome — a complex of enzymes responsible for the destruction of unnecessary or damaged proteins — dipeptide repeat (DPR) proteins associated with C9ORF72 gene repeat expansions (the most common genetic cause of amyotrophic lateral sclerosis) can travel between nerve cells…
The onset and early progression of motor and cognitive symptoms, specific by disease type to each amyotrophic lateral sclerosis (ALS) patient, are determined by age and sex, and to some extent by mutations in ALS genes, a large data study has found. The study, “ALS phenotype is influenced…
AB Science plans to launch a Phase 3 clinical trial testing the safety and effectiveness of its tyrosine kinase inhibitor masitinib as an add-on treatment for people with amyotrophic lateral sclerosis (ALS). Its announcement follows U.S. Food and Drug Administration (FDA) approval of the company’s investigational new…
Get regular updates to your inbox.
